To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with metastatic cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Metastatic Cancer
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with metastatic cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
A Study of the ApricityCare Program for Early Detection and Management of Treatment-related Adverse Events in Patients With Metastatic Cancer
-
MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
M.D. Anderson Cancer Center,
2027-11-01